⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
Ray Therapeutics Announces Upsized and Oversubscribed $125 Million Series B Financing for Vision Restoration Treatments
businesswire.com
JHG
BEN
MRK
Immuno-Oncology Drugs Market Opportunity Analysis and Forecast Report 2026-2035: Merck & Co. Remains a Dominant Force, Supported by the Commercial Success of Keytruda
globenewswire.com
MRK
BMY
GILD
TAK
Oncolytic Virus Immunotherapy Market Landscape Report 2026: A $5 Opportunity by 2031 - Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insights
globenewswire.com
MRK
BMY
AMGN
REPL
Trispecific Antibodies Market Landscape Report 2026: Opportunity and Proprietary Insights - 90 Trispecific Antibodies by Company, Country, Indication & Phase
globenewswire.com
MRK
JNJ
ABBV
OPK
Lung Cancer Therapeutics Market to Reach $49.5 Billion by 2030, Driven by Rising Cancer Incidence and R&D Investment Surge
globenewswire.com
AZN
MRK
BMY
PFE
AMGN
Arrayed CRISPR Screening Market Presents Lucrative Opportunities Through 2026-2030: Total Revenue to Grow by $1.64 Billion at 17.7% CAGR
globenewswire.com
TMO
MRK
GEHC
AZN
AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL USA - English USA - English
prnewswire.com
MRK
GSK
GILD
AACR 2026 Oral Presentation: Abogen Presents Preliminary Results of ABO2203 (mRNA-Encoded CD3×CD19 TCE) from First-in-Human Clinical Study in R/R B-NHL USA - English USA - English
prnewswire.com
MRK
GSK
GILD
Foundation Fighting Blindness to Host United in Vision 2026 Conference in Partnership with Retina International World Congress
prnewswire.com
AMGN
ALKS
BLCO
AMR
MRK
REGN
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
businesswire.com
MRK